Evidence map›Paper›PMID 40723221›Full record

ReviewCancers2025

Artificial Intelligence in Advancing Inflammatory Bowel Disease Management: Setting New Standards.

Nunzia Labarile, Alessandro Vitello, Emanuele Sinagra, Olga Maria Nardone, Giulio Calabrese, Federico Bonomo, Marcello Maida, Marietta Iacucci

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nunzia LabarileDepartment of Gastroenterology, National Institute of Gastroenterology-IRCCS "Saverio de Bellis"-Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-8512-7726
Alessandro VitelloDepartment of Medicine and Surgery, University of Enna 'Kore', 94100 Enna, Italy.ORCID 0000-0001-9099-9468
Emanuele SinagraGastroenterology Unit, Fondazione Istituto San Raffaele Giglio, 90015 Cefalù, Italy.
Olga Maria NardoneGastroenterology Unit, Department of Public Health, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-9554-4785
Giulio CalabreseGastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-0802-3173
Federico BonomoGastroenterology Unit, Umberto I Hospital, 94100 Enna, Italy.
Marcello MaidaDepartment of Medicine and Surgery, University of Enna 'Kore', 94100 Enna, Italy.ORCID 0000-0002-4992-9289
Marietta IacucciAPC Microbiome Ireland, College of Medicine and Health, University College Cork, T12 YN60 Cork, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionArtificial intelligence (AI) is increasingly being applied to improve the diagnosis and management of inflammatory bowel disease (IBD). AIMS AND

methodsWe conducted a narrative review of the literature on AI applications in IBD endoscopy, focusing on diagnosis, disease activity assessment, therapy prediction, and detection of dysplasia.

resultsAI systems have demonstrated high accuracy in assessing endoscopic and histological disease activity in ulcerative colitis and Crohn's disease, with performance comparable to expert clinicians. Machine learning models can predict response to biologics and risk of complications. AI-assisted technologies like confocal laser endomicroscopy enable real-time histological assessment. Computer-aided detection systems improve identification of dysplastic lesions during surveillance. Challenges remain, including need for larger datasets, external validation, and addressing potential biases.

conclusionsAI has significant potential to enhance IBD care by providing rapid, objective assessments of disease activity, predicting outcomes, and assisting in dysplasia surveillance. However, further validation in diverse populations and prospective studies are needed before widespread clinical implementation. With ongoing advances, AI is poised to become a valuable tool to support clinical decision-making and improve patient outcomes in IBD. Addressing methodological, regulatory, and cost barriers will be crucial for the successful integration of AI into routine IBD management.

Indexed as

artificial intelligenceCrohn’s diseaseinflammatory bowel diseaseulcerative colitis

Identifiers

PMID40723221
PMCPMC12293501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.